PET/MRI: pictorial review of hepatobiliary and pancreatic applications.
Hepatobiliary
MRI
Oncology
PET
Pancreatic
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
received:
17
07
2024
accepted:
25
08
2024
revised:
20
08
2024
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
10
9
2024
Statut:
aheadofprint
Résumé
PET and MRI both play valuable roles in the management of hepatobiliary and pancreatic (HBP) malignancies. Simultaneous PET/MRI combines the excellent soft-tissue resolution and anatomic details from MRI with functional information from PET in a single comprehensive examination. MRI is the main imaging modality in evaluating HCC, playing important roles in screening, characterization, local extent, and evaluating tumor response, whereas
Identifiants
pubmed: 39254711
doi: 10.1007/s00261-024-04548-6
pii: 10.1007/s00261-024-04548-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Currie GM, Kamvosoulis P, Bushong S. PET/MRI, part 2: technologic principles. J Nucl Med Technol. 2021;49(3):217-25. https://doi.org/10.2967/jnmt.120.261862 .
doi: 10.2967/jnmt.120.261862
pubmed: 33722925
Shortman RI, Neriman D, Hoath J, Millner L, Endozo R, Azzopardi G, et al. A comparison of the psychological burden of PET/MRI and PET/CT scans and association to initial state anxiety and previous imaging experiences. Br J Radiol. 2015;88(1052):20150121. https://doi.org/10.1259/bjr.20150121 .
doi: 10.1259/bjr.20150121
pubmed: 26090825
pmcid: 4651398
Grueneisen J, Schaarschmidt BM, Beiderwellen K, Schulze-Hagen A, Heubner M, Kinner S, et al. Diagnostic value of diffusion-weighted imaging in simultaneous
doi: 10.2967/jnumed.114.146886
pubmed: 25453042
Queiroz MA, Hüllner M, Kuhn F, Huber G, Meerwein C, Kollias S, et al. Use of diffusion-weighted imaging (DWI) in PET/MRI for head and neck cancer evaluation. Eur J Nucl Med Mol Imaging. 2014;41(12):2212-21. https://doi.org/10.1007/s00259-014-2867-7 .
doi: 10.1007/s00259-014-2867-7
pubmed: 25091219
Parikh N, Friedman KP, Shah SN, Chandarana H. Practical guide for implementing hybrid PET/MR clinical service: lessons learned from our experience. Abdom Imaging. 2015;40(6):1366-73. https://doi.org/10.1007/s00261-015-0444-6 .
doi: 10.1007/s00261-015-0444-6
pubmed: 25985966
pmcid: 4534342
Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med. 2005;46(10):1753-9.
pubmed: 16204727
Jha P, Bijan B. PET/CT for pancreatic malignancy: potential and pitfalls. J Nucl Med Technol. 2015;43(2):92-7. https://doi.org/10.2967/jnmt.114.145458 .
doi: 10.2967/jnmt.114.145458
pubmed: 25857417
Yan Q, Yan X, Yang X, Li S, Song J. The use of PET/MRI in radiotherapy. Insights Imaging. 2024;15(1):63. https://doi.org/10.1186/s13244-024-01627-6 .
doi: 10.1186/s13244-024-01627-6
pubmed: 38411742
pmcid: 10899128
Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, et al. Impact of the (18)F-FDG-PET/MRI on metastatic staging in patients with hepatocellular carcinoma: initial results from 104 patients. J Clin Med. 2021;10(17). https://doi.org/10.3390/jcm10174017 .
doi: 10.3390/jcm10174017
pubmed: 34501465
pmcid: 8432497
Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A practical guideline for hepatocellular carcinoma screening in patients at risk. Mayo Clin Proc Innov Qual Outcomes. 2019;3(3):302-10. https://doi.org/10.1016/j.mayocpiqo.2019.04.005 .
doi: 10.1016/j.mayocpiqo.2019.04.005
pubmed: 31485568
pmcid: 6713857
Cho E, Jun CH, Kim BS, Son DJ, Choi WS, Choi SK.
doi: 10.5152/tjg.2015.0152
pubmed: 26039005
Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011;197(2):W260-5. https://doi.org/10.2214/ajr.11.6995 .
doi: 10.2214/ajr.11.6995
pubmed: 21785051
Ida Y, Tamai H, Shingaki N, Shimizu R, Maeshima S, Maekita T, et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with small hepatocellular carcinoma treated by radiofrequency ablation. Cancer Imaging. 2020;20(1):74. https://doi.org/10.1186/s40644-020-00356-5 .
doi: 10.1186/s40644-020-00356-5
pubmed: 33076990
pmcid: 7574337
Hassan OT, Behr SC, Ohliger MA, Fowler KJ, Gill RM, Fidelman N, et al. Per-patient negative predictive value of the CT and MRI liver imaging reporting and data system version 2018 treatment response algorithm for hepatocellular carcinoma. Radiology. 2023;309(3):e222776. https://doi.org/10.1148/radiol.222776 .
doi: 10.1148/radiol.222776
pubmed: 38112541
Nashi IT, Morsy HA, Shalaby MH, Ali SA. Role of 18F-FDG PET/CT in assessment of HCC patients after therapeutic interventions compared to DW MRI. Egypt J Radiol Nucl Med. 2022;53(1):186. https://doi.org/10.1186/s43055-022-00867-0 .
doi: 10.1186/s43055-022-00867-0
Song YS, Paeng JC, Kim HC, Chung JW, Cheon GJ, Chung JK, et al. PET/CT-based dosimetry in 90Y-microsphere selective internal radiation therapy: single cohort comparison with pretreatment planning on (99m)Tc-MAA imaging and correlation with treatment efficacy. Medicine. 2015;94(23):e945. https://doi.org/10.1097/md.0000000000000945 .
doi: 10.1097/md.0000000000000945
pubmed: 26061323
pmcid: 4616469
DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755-62. https://doi.org/10.1097/01.sla.0000251366.62632.d3 .
doi: 10.1097/01.sla.0000251366.62632.d3
pubmed: 17457168
pmcid: 1877058
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557-88. https://doi.org/10.1038/s41575-020-0310-z .
doi: 10.1038/s41575-020-0310-z
pubmed: 32606456
pmcid: 7447603
Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, et al. Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol. 2022;27(5):100737. https://doi.org/10.1016/j.aohep.2022.100737 .
doi: 10.1016/j.aohep.2022.100737
pubmed: 35809836
Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:98-107. https://doi.org/10.1111/liv.14086 .
doi: 10.1111/liv.14086
pubmed: 30831002
Ferrone C, Goyal L, Qadan M, Gervais D, Sahani DV, Zhu AX, et al. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2020;47(8):1871-84. https://doi.org/10.1007/s00259-019-04558-3 .
doi: 10.1007/s00259-019-04558-3
pubmed: 31705172
Yoo J, Lee JM, Yoon JH, Joo I, Lee DH. Additional value of integrated (18)F-FDG PET/MRI for evaluating biliary tract cancer: comparison with contrast-enhanced CT. Korean J Radiol. 2021;22(5):714-24. https://doi.org/10.3348/kjr.2020.0689 .
doi: 10.3348/kjr.2020.0689
pubmed: 33660461
pmcid: 8076821
Pang L, Mao W, Zhang Y, Liu G, Hu P, Chen S, et al. Comparison of (18)F-FDG PET/MR and PET/CT for pretreatment TNM staging of hilar cholangiocarcinoma. Abdom Radiol (NY). 2023;48(8):2537-46. https://doi.org/10.1007/s00261-023-03925-x .
doi: 10.1007/s00261-023-03925-x
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. https://doi.org/10.3322/caac.21551 .
doi: 10.3322/caac.21551
pubmed: 30620402
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21. https://doi.org/10.1158/0008-5472.Can-14-0155 .
doi: 10.1158/0008-5472.Can-14-0155
pubmed: 24840647
Joo I, Lee JM, Lee DH, Lee ES, Paeng JC, Lee SJ, et al. Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology. 2017;282(1):149-59. https://doi.org/10.1148/radiol.2016152798 .
doi: 10.1148/radiol.2016152798
pubmed: 27556273
Wang XY, Yang F, Jin C, Fu DL. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol. 2014;20(42):15580-9. https://doi.org/10.3748/wjg.v20.i42.15580 .
doi: 10.3748/wjg.v20.i42.15580
pubmed: 25400441
pmcid: 4229522
Beiderwellen K, Geraldo L, Ruhlmann V, Heusch P, Gomez B, Nensa F, et al. Accuracy of [18F]FDG PET/MRI for the detection of liver metastases. PLoS One. 2015;10(9):e0137285. https://doi.org/10.1371/journal.pone.0137285 .
doi: 10.1371/journal.pone.0137285
pubmed: 26335246
pmcid: 4559465
Liu RC, Traverso LW. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc. 2005;19(5):638-42. https://doi.org/10.1007/s00464-004-8165-x .
doi: 10.1007/s00464-004-8165-x
pubmed: 15776215
Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The role of 18F-FDG PET/CT and PET/MRI in pancreatic ductal adenocarcinoma. Abdom Radiol. 2018;43(2):415-34. https://doi.org/10.1007/s00261-017-1374-2 .
doi: 10.1007/s00261-017-1374-2
pubmed: 29143875
Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749-56. https://doi.org/10.1002/cncr.27636 .
doi: 10.1002/cncr.27636
pubmed: 22605518
Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, et al. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol. 2014;7(5):644-9. https://doi.org/10.1016/j.tranon.2014.07.005 .
doi: 10.1016/j.tranon.2014.07.005
pubmed: 25389460
pmcid: 4225651
Harder FN, Jungmann F, Kaissis GA, Lohöfer FK, Ziegelmayer S, Havel D, et al. [(18)F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Res. 2021;11(1):70. https://doi.org/10.1186/s13550-021-00808-4 .
doi: 10.1186/s13550-021-00808-4
pubmed: 34322781
pmcid: 8319249
Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, et al. Early response assessment in pancreatic ductal adenocarcinoma through integrated PET/MRI. AJR Am J Roentgenol. 2018;211(5):1010-9. https://doi.org/10.2214/ajr.18.19602 .
doi: 10.2214/ajr.18.19602
pubmed: 30063366
Cives M, Strosberg J. An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park). 2014;28(9):749-56, 58.
pubmed: 25224471
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604-20. https://doi.org/10.1093/annonc/mdv041 .
doi: 10.1093/annonc/mdv041
pubmed: 25646366
Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23(4):43. https://doi.org/10.1007/s11912-021-01029-7 .
doi: 10.1007/s11912-021-01029-7
pubmed: 33719003
pmcid: 8118193
Refardt J, Hofland J, Wild D, Christ E. New Directions in imaging neuroendocrine neoplasms. Curr Oncol Rep. 2021;23(12):143. https://doi.org/10.1007/s11912-021-01139-2 .
doi: 10.1007/s11912-021-01139-2
pubmed: 34735669
pmcid: 8568754
Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer. 2018;18(1):1122. https://doi.org/10.1186/s12885-018-5057-3 .
doi: 10.1186/s12885-018-5057-3
pubmed: 30445941
pmcid: 6240263
Galgano SJ, Iravani A, Bodei L, El-Haddad G, Hofman MS, Kong G. Imaging of neuroendocrine neoplasms: monitoring treatment response—AJR expert panel narrative review. AJR Am J Roentgenol. 2022. https://doi.org/10.2214/AJR.21.27159 .
doi: 10.2214/AJR.21.27159
pubmed: 34985313
Virarkar MK, Montanarella M, Itani M, Calimano-Ramirez L, Gopireddy D, Bhosale P. PET/MRI imaging in neuroendocrine neoplasm. Abdom Radiol. 2023;48(12):3585-600. https://doi.org/10.1007/s00261-022-03757-1 .
doi: 10.1007/s00261-022-03757-1
pubmed: 36525051
Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679-86. https://doi.org/10.1002/ijc.30400 .
doi: 10.1002/ijc.30400
pubmed: 27553864
Pirasteh A, Riedl C, Mayerhoefer ME, Giancipoli RG, Larson SM, Bodei L. PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype? Clin Transl Imaging. 2019;7(6):405-13. https://doi.org/10.1007/s40336-019-00344-1 .
doi: 10.1007/s40336-019-00344-1
pubmed: 33282794
pmcid: 7717609
Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, et al. Evaluation of (68)Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with (68)Ga-DOTATOC PET/CT. Eur Radiol. 2017;27(10):4091-9. https://doi.org/10.1007/s00330-017-4803-2 .
doi: 10.1007/s00330-017-4803-2
pubmed: 28439648
Morse B, Jeong D, Thomas K, Diallo D, Strosberg JR. Magnetic resonance imaging of neuroendocrine tumor hepatic metastases: does hepatobiliary phase imaging improve lesion conspicuity and interobserver agreement of lesion measurements? Pancreas. 2017;46(9):1219-24. https://doi.org/10.1097/MPA.0000000000000920 .
doi: 10.1097/MPA.0000000000000920
pubmed: 28902795
Seith F, Schraml C, Reischl G, Nikolaou K, Pfannenberg C, la Fougère C, et al. Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. Radiol Med. 2018;123(11):860-70. https://doi.org/10.1007/s11547-018-0917-0 .
doi: 10.1007/s11547-018-0917-0
pubmed: 29961229
Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V, et al. Comparative performance of
doi: 10.2967/jnumed.115.167486
pubmed: 26742715
Centeno BA. Pathology of liver metastases. Cancer Control. 2006;13(1):13-26. https://doi.org/10.1177/107327480601300103 .
doi: 10.1177/107327480601300103
pubmed: 16508622
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. https://doi.org/10.3322/caac.20073 .
doi: 10.3322/caac.20073
pubmed: 20610543
Qian J. Interventional therapies of unresectable liver metastases. J Cancer Res Clin Oncol. 2011;137(12):1763-72. https://doi.org/10.1007/s00432-011-1026-9 .
doi: 10.1007/s00432-011-1026-9
pubmed: 21909952
Schulz A, Viktil E, Godt JC, Johansen CK, Dormagen JB, Holtedahl JE, et al. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol. 2016;57(9):1040-8. https://doi.org/10.1177/0284185115617349 .
doi: 10.1177/0284185115617349
pubmed: 26622057
Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, et al. The impact of 18F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging. 2007;34(12):1906-14. https://doi.org/10.1007/s00259-007-0518-y .
doi: 10.1007/s00259-007-0518-y
pubmed: 17713766
Hong SB, Choi SH, Kim KW, Park SH, Kim SY, Lee SJ, et al. Diagnostic performance of [(18)F]FDG-PET/MRI for liver metastasis in patients with primary malignancy: a systematic review and meta-analysis. Eur Radiol. 2019;29(7):3553-63. https://doi.org/10.1007/s00330-018-5909-x .
doi: 10.1007/s00330-018-5909-x
pubmed: 30715585
Furtado FS, Suarez-Weiss KE, Vangel M, Clark JW, Cusack JC, Hong T, et al. Clinical impact of PET/MRI in oligometastatic colorectal cancer. Br J Cancer. 2021;125(7):975-82. https://doi.org/10.1038/s41416-021-01494-8 .
doi: 10.1038/s41416-021-01494-8
pubmed: 34282295
pmcid: 8476553
Zirakchian Zadeh M. PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis on (18)F-FDG. Clin Exp Metastasis. 2023;40(6):465-91. https://doi.org/10.1007/s10585-023-10231-9 .
doi: 10.1007/s10585-023-10231-9
Crimì F, Valeggia S, Baffoni L, Stramare R, Lacognata C, Spolverato G, et al. [18F]FDG PET/MRI in rectal cancer. Ann Nucl Med. 2021;35(3):281-90. https://doi.org/10.1007/s12149-021-01580-0 .
doi: 10.1007/s12149-021-01580-0
pubmed: 33517562
pmcid: 7902586
Tan GJ, Berlangieri SU, Lee ST, Scott AM. FDG PET/CT in the liver: lesions mimicking malignancies. Abdom Imaging. 2014;39(1):187-95. https://doi.org/10.1007/s00261-013-0043-3 .
doi: 10.1007/s00261-013-0043-3
pubmed: 24233161
Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Jr., Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133(5):510-5; discussion 5-6. https://doi.org/10.1001/archsurg.133.5.510 .
doi: 10.1001/archsurg.133.5.510
pubmed: 9605913
Park HJ, Kim SH, Jang KM, Lee SJ, Park MJ, Choi D. Differentiating hepatic abscess from malignant mimickers: value of diffusion-weighted imaging with an emphasis on the periphery of the lesion. J Magn Reson Imaging. 2013;38(6):1333-41. https://doi.org/10.1002/jmri.24112 .
doi: 10.1002/jmri.24112
pubmed: 23559325
Park MS, Kim TK, Kim KW, Park SW, Lee JK, Kim JS, et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology. 2004;233(1):234-40. https://doi.org/10.1148/radiol.2331031446 .
doi: 10.1148/radiol.2331031446
pubmed: 15333766
Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33(5):1029-35. https://doi.org/10.1053/jhep.2001.23912 .
doi: 10.1053/jhep.2001.23912
pubmed: 11343227
Reinhardt MJ, Strunk H, Gerhardt T, Roedel R, Jaeger U, Bucerius J, et al. Detection of Klatskin’s tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med. 2005;46(7):1158-63.
pubmed: 16000285
Choi EK, Yoo Ie R, Kim SH, O JH, Choi WH, Na SJ, et al. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease. Clin Nucl Med. 2013;38(3):e106-11. https://doi.org/10.1097/RLU.0b013e318266f402 .
doi: 10.1097/RLU.0b013e318266f402
Nishiyama Y, Yamamoto Y, Kimura N, Miki A, Sasakawa Y, Wakabayashi H, et al. Comparison of early and delayed FDG PET for evaluation of biliary stricture. Nucl Med Commun. 2007;28(12):914-9. https://doi.org/10.1097/MNM.0b013e3282f1ac85 .
doi: 10.1097/MNM.0b013e3282f1ac85
pubmed: 18090217
Wakabayashi H, Akamoto S, Yachida S, Okano K, Izuishi K, Nishiyama Y, et al. Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol. 2005;31(10):1175-9. https://doi.org/10.1016/j.ejso.2005.05.012 .
doi: 10.1016/j.ejso.2005.05.012
pubmed: 16019182
Soto JA, Alvarez O, Lopera JE, Múnera F, Restrepo JC, Correa G. Biliary obstruction: findings at MR cholangiography and cross-sectional MR imaging. Radiographics. 2000;20(2):353-66. https://doi.org/10.1148/radiographics.20.2.g00mc06353 .
doi: 10.1148/radiographics.20.2.g00mc06353
pubmed: 10715336
Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol. 2013;201(1):80-96. https://doi.org/10.2214/ajr.13.10706 .
doi: 10.2214/ajr.13.10706
pubmed: 23789661
Agnello F, Salvaggio G, Cabibbo G, Maida M, Lagalla R, Midiri M, et al. Imaging appearance of treated hepatocellular carcinoma. World J Hepatol. 2013;5(8):417-24. https://doi.org/10.4254/wjh.v5.i8.417 .
doi: 10.4254/wjh.v5.i8.417
pubmed: 24023980
pmcid: 3767840
Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, et al. Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma. Nucl Med Mol Imaging. 2012;46(2):102-10. https://doi.org/10.1007/s13139-012-0138-8 .
doi: 10.1007/s13139-012-0138-8
pubmed: 24900042
pmcid: 4042986
Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology. 2011;260(3):752-61. https://doi.org/10.1148/radiol.11102330 .
doi: 10.1148/radiol.11102330
pubmed: 21771960
Semaan S, Makkar J, Lewis S, Chatterji M, Kim E, Taouli B. Imaging of Hepatocellular Carcinoma Response After (90)Y Radioembolization. AJR Am J Roentgenol. 2017;209(5):W263-w76. https://doi.org/10.2214/ajr.17.17993 .
doi: 10.2214/ajr.17.17993
pubmed: 29072955
Chen W, Zhuang H, Cheng G, Torigian DA, Alavi A. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Ann Nucl Med. 2013;27(1):58-64. https://doi.org/10.1007/s12149-012-0656-6 .
doi: 10.1007/s12149-012-0656-6
pubmed: 23054830
Fowler KJ, Maughan NM, Laforest R, Saad NE, Sharma A, Olsen J, et al. PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response. Cardiovasc Intervent Radiol. 2016;39(6):855-64. https://doi.org/10.1007/s00270-015-1285-y .
doi: 10.1007/s00270-015-1285-y
pubmed: 26721589
Evangelista L, Zucchetta P, Moletta L, Serafini S, Cassarino G, Pegoraro N, et al. The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review. Ann Nucl Med. 2021;35(7):767-76. https://doi.org/10.1007/s12149-021-01629-0 .
doi: 10.1007/s12149-021-01629-0
pubmed: 34047926
pmcid: 8197718
Gnanasegaran G, Agrawal K, Wan S. 18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies. PET Clin. 2022;17(3):369-88. https://doi.org/10.1016/j.cpet.2022.03.007 .
doi: 10.1016/j.cpet.2022.03.007
pubmed: 35717098
Zimmermann C, Distler M, Jentsch C, Blum S, Folprecht G, Zöphel K, et al. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). Strahlenther Onkol. 2021;197(1):19-26. https://doi.org/10.1007/s00066-020-01654-4 .
doi: 10.1007/s00066-020-01654-4
pubmed: 32638040
Song H, Guja KE, Iagaru A. (18)F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD). Semin Nucl Med. 2021;51(4):392-403. https://doi.org/10.1053/j.semnuclmed.2020.12.009 .
doi: 10.1053/j.semnuclmed.2020.12.009
pubmed: 33455722
Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World J Gastroenterol. 2018;24(45):5081-94. https://doi.org/10.3748/wjg.v24.i45.5081 .
doi: 10.3748/wjg.v24.i45.5081
pubmed: 30568386
pmcid: 6288653
Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, et al. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26(1):50-60. https://doi.org/10.1111/j.1432-2277.2012.01572.x .
doi: 10.1111/j.1432-2277.2012.01572.x
pubmed: 23106431
Zucchetta P, Lacognata C, Girardi F, Spimpolo A, Crimì F, Cabrelle G, et al. [18F]FDG PET/MRI in the follow-up of hepatocellular carcinoma after liver transplantation. Nucl Med Commun. 2022;43(3):359-67. https://doi.org/10.1097/mnm.0000000000001518 .
doi: 10.1097/mnm.0000000000001518
pubmed: 35019883
pmcid: 9897275
Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, et al. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91(1):101-9. https://doi.org/10.1159/000265561 .
doi: 10.1159/000265561
pubmed: 19996582
Choi SJ, Choi SH, Lee DY, Lee JS, Kim DW, Jang JK. Diagnostic value of [(68) Ga]Ga-DOTA-labeled-somatostatin analogue PET/MRI for detecting liver metastasis in patients with neuroendocrine tumors: a systematic review and meta-analysis. Eur Radiol. 2022;32(7):4628-37. https://doi.org/10.1007/s00330-021-08527-z .
doi: 10.1007/s00330-021-08527-z
pubmed: 35092473
Ramage J, Naraev BG, Halfdanarson TR. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Semin Oncol. 2018;45(4):236-48. https://doi.org/10.1053/j.seminoncol.2018.08.004 .
doi: 10.1053/j.seminoncol.2018.08.004
pubmed: 30539715
Barachini O, Bernt R, Mirzaei S, Pirich C, Hergan K, Zandieh S. The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract. BMC Med Imaging. 2020;20(1):22. https://doi.org/10.1186/s12880-020-00424-z .
doi: 10.1186/s12880-020-00424-z
pubmed: 32093632
pmcid: 7038547
Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, et al. Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT. Clin Nucl Med. 2019;44(9):702-6. https://doi.org/10.1097/rlu.0000000000002701 .
doi: 10.1097/rlu.0000000000002701
pubmed: 31348076
Rajaraman V, Meenakshi LA, Selvaraj AJ, Pottakkat B, Halanaik D. Role of 68 Ga-FAPI PET/CT in Assessing Hepatobiliary Malignancies : A Prospective Pilot Study. Clin Nucl Med. 2023;48(6):e281-e8. https://doi.org/10.1097/rlu.0000000000004641 .
doi: 10.1097/rlu.0000000000004641
pubmed: 37019124
Siripongsatian D, Promteangtrong C, Kunawudhi A, Kiatkittikul P, Boonkawin N, Chinnanthachai C, et al. Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [(18)F]F-FDG PET/CT in Patients with Liver Malignancies. Mol Imaging Biol. 2022;24(5):818-29. https://doi.org/10.1007/s11307-022-01732-2 .
doi: 10.1007/s11307-022-01732-2
pubmed: 35486293
pmcid: 9053129
Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [(68)Ga]Ga-FAPI-04 PET/CT versus MRI and [(18)F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(5):1604-17. https://doi.org/10.1007/s00259-020-05095-0 .
doi: 10.1007/s00259-020-05095-0
pubmed: 33179149
Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med. 2004;45(3):519-25.
pubmed: 15001697